ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers
Protocol ID
OZM-075 (Hypermutant Cancer)
Disease (Sub Disease)
All Tumour Types
Diagnosis Stage
Relapse/ refractory
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
The Hospital for Sick Children
Collaborators
Bristol-Myers Squibb
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Pilot
Age Eligibility
12 months to 25 years
International registry ID's
NCT02992964
Back to Registry
Study Title Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers
Protocol ID OZM-075 (Hypermutant Cancer)
Disease (Sub Disease) All Tumour Types
Diagnosis Stage Relapse/ refractory
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ The Hospital for Sick Children
Collaborators Bristol-Myers Squibb
Links https://clinicaltrials.gov/ct2/show/study/NCT02992964
Trial Status Closed to Recruitment
Trial Open Date 06/12/2019
Study Type Treatment
Phase Pilot
Age Eligibility 12 months to 25 years
International registry ID's NCT02992964

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.